Clinical effectiveness of evidence-based guidelines for pain management of terminal cancer patients in Japan

Tsuguya Fukui, Osamu Takashi, Mahbubur Rahman, Keiko Iino, Yosuke Uchitomi, Setsuro Ogawa, Midori Kita, Izo Kimijima, Hitoshi Kondo, Michihiro Shino, Yoko Takumi, Akira Tsuneto, Keiko Hamaguchi, Maki Matsumoto, Taketo Mukaiyama, Makoto Yamamuro, Akihiko Watanabe, Osamu Setoyama, Kazuaki Hiraga

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The Japanese Society for Palliative Medicine (JSPM) set guidelines for cancer pain management in 1999. However, the clinical effectiveness of the guidelines has not yet been examined. Methods: Two groups of consecutive patients with cancer admitted to 37 national hospitals (collaborating hospitals for pain management research in Japan) were recruited, one from August to September 1999 (who received the standard treatment in use before the distribution of JSPM guidelines) and the other from July 2000 to May 2001 (who received treatment after the distribution of JSPM guidelines). Demographics, type of cancer and other baseline information were recorded for both groups. In addition, the intensity of pain (evaluated on a 4-level scale of none, mild, moderate, severe; and a visual analog scale of 0 to 100), its duration, source and location were recorded at base line, 1 week and 2 weeks after the start of pain management for two groups and compared by statistical methods. Results: A total of 314 cancer patients received the standard pre-guidelines treatment from August to September 1999 and 106 patients received the post-guidelines treatment from July 2000 to May 2001. No significant differences have been observed between the two groups in terms of baseline characteristics. There were more patients with lung cancer in the pre-guidelines treatment group and more with gastric cancer in the post-guidelines treatment group. More oral opioids (P=0.004) and more adjuvant drugs such as nonsteroidal anti-inflammatory drugs (P=0.001) and hydroxyzine (P=0.001) were used in the post-guidelines treatment group than in the pre-guidelines treatment group and the opposite was true for intravenous (P = 0.022) and suppository (P = 0.041) opioids. More patients in the post-guidelines treatment group became pain free after 2 weeks compared to those in the pre-guidelines treatment group (14.7% vs. 8.8%) (P = 0.036). Moreover, significantly fewer adverse reactions and more recovery from the adverse reactions which did occur were found in the post-guidelines treatment group than in the pre-guidelines treatment group. Conclusion: The implementation of JSPM pain management guidelines for cancer patients was effective in increasing the proportion of patients relieved of pain and in reducing adverse reactions to opioids.

Original languageEnglish (US)
Pages (from-to)216-223
Number of pages8
JournalJapan Medical Association Journal
Volume48
Issue number5
StatePublished - May 2005
Externally publishedYes

Fingerprint

Pain Management
Japan
Guidelines
Neoplasms
Therapeutics
Opioid Analgesics
Hydroxyzine
Pain
Suppositories
Visual Analog Scale
Pharmaceutical Preparations
Stomach Neoplasms
Lung Neoplasms
Anti-Inflammatory Agents

Keywords

  • Cancer pain
  • Clinical effectiveness
  • Japanese Society for Palliative Medicine
  • Opioids and non-opioid analgesics
  • Pain management
  • Treatment guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fukui, T., Takashi, O., Rahman, M., Iino, K., Uchitomi, Y., Ogawa, S., ... Hiraga, K. (2005). Clinical effectiveness of evidence-based guidelines for pain management of terminal cancer patients in Japan. Japan Medical Association Journal, 48(5), 216-223.

Clinical effectiveness of evidence-based guidelines for pain management of terminal cancer patients in Japan. / Fukui, Tsuguya; Takashi, Osamu; Rahman, Mahbubur; Iino, Keiko; Uchitomi, Yosuke; Ogawa, Setsuro; Kita, Midori; Kimijima, Izo; Kondo, Hitoshi; Shino, Michihiro; Takumi, Yoko; Tsuneto, Akira; Hamaguchi, Keiko; Matsumoto, Maki; Mukaiyama, Taketo; Yamamuro, Makoto; Watanabe, Akihiko; Setoyama, Osamu; Hiraga, Kazuaki.

In: Japan Medical Association Journal, Vol. 48, No. 5, 05.2005, p. 216-223.

Research output: Contribution to journalArticle

Fukui, T, Takashi, O, Rahman, M, Iino, K, Uchitomi, Y, Ogawa, S, Kita, M, Kimijima, I, Kondo, H, Shino, M, Takumi, Y, Tsuneto, A, Hamaguchi, K, Matsumoto, M, Mukaiyama, T, Yamamuro, M, Watanabe, A, Setoyama, O & Hiraga, K 2005, 'Clinical effectiveness of evidence-based guidelines for pain management of terminal cancer patients in Japan', Japan Medical Association Journal, vol. 48, no. 5, pp. 216-223.
Fukui, Tsuguya ; Takashi, Osamu ; Rahman, Mahbubur ; Iino, Keiko ; Uchitomi, Yosuke ; Ogawa, Setsuro ; Kita, Midori ; Kimijima, Izo ; Kondo, Hitoshi ; Shino, Michihiro ; Takumi, Yoko ; Tsuneto, Akira ; Hamaguchi, Keiko ; Matsumoto, Maki ; Mukaiyama, Taketo ; Yamamuro, Makoto ; Watanabe, Akihiko ; Setoyama, Osamu ; Hiraga, Kazuaki. / Clinical effectiveness of evidence-based guidelines for pain management of terminal cancer patients in Japan. In: Japan Medical Association Journal. 2005 ; Vol. 48, No. 5. pp. 216-223.
@article{7ca7a13b09da4e0da2d68336e9d566d5,
title = "Clinical effectiveness of evidence-based guidelines for pain management of terminal cancer patients in Japan",
abstract = "Background: The Japanese Society for Palliative Medicine (JSPM) set guidelines for cancer pain management in 1999. However, the clinical effectiveness of the guidelines has not yet been examined. Methods: Two groups of consecutive patients with cancer admitted to 37 national hospitals (collaborating hospitals for pain management research in Japan) were recruited, one from August to September 1999 (who received the standard treatment in use before the distribution of JSPM guidelines) and the other from July 2000 to May 2001 (who received treatment after the distribution of JSPM guidelines). Demographics, type of cancer and other baseline information were recorded for both groups. In addition, the intensity of pain (evaluated on a 4-level scale of none, mild, moderate, severe; and a visual analog scale of 0 to 100), its duration, source and location were recorded at base line, 1 week and 2 weeks after the start of pain management for two groups and compared by statistical methods. Results: A total of 314 cancer patients received the standard pre-guidelines treatment from August to September 1999 and 106 patients received the post-guidelines treatment from July 2000 to May 2001. No significant differences have been observed between the two groups in terms of baseline characteristics. There were more patients with lung cancer in the pre-guidelines treatment group and more with gastric cancer in the post-guidelines treatment group. More oral opioids (P=0.004) and more adjuvant drugs such as nonsteroidal anti-inflammatory drugs (P=0.001) and hydroxyzine (P=0.001) were used in the post-guidelines treatment group than in the pre-guidelines treatment group and the opposite was true for intravenous (P = 0.022) and suppository (P = 0.041) opioids. More patients in the post-guidelines treatment group became pain free after 2 weeks compared to those in the pre-guidelines treatment group (14.7{\%} vs. 8.8{\%}) (P = 0.036). Moreover, significantly fewer adverse reactions and more recovery from the adverse reactions which did occur were found in the post-guidelines treatment group than in the pre-guidelines treatment group. Conclusion: The implementation of JSPM pain management guidelines for cancer patients was effective in increasing the proportion of patients relieved of pain and in reducing adverse reactions to opioids.",
keywords = "Cancer pain, Clinical effectiveness, Japanese Society for Palliative Medicine, Opioids and non-opioid analgesics, Pain management, Treatment guidelines",
author = "Tsuguya Fukui and Osamu Takashi and Mahbubur Rahman and Keiko Iino and Yosuke Uchitomi and Setsuro Ogawa and Midori Kita and Izo Kimijima and Hitoshi Kondo and Michihiro Shino and Yoko Takumi and Akira Tsuneto and Keiko Hamaguchi and Maki Matsumoto and Taketo Mukaiyama and Makoto Yamamuro and Akihiko Watanabe and Osamu Setoyama and Kazuaki Hiraga",
year = "2005",
month = "5",
language = "English (US)",
volume = "48",
pages = "216--223",
journal = "Asian Medical Journal",
issn = "1346-8650",
publisher = "Japan Medical Association",
number = "5",

}

TY - JOUR

T1 - Clinical effectiveness of evidence-based guidelines for pain management of terminal cancer patients in Japan

AU - Fukui, Tsuguya

AU - Takashi, Osamu

AU - Rahman, Mahbubur

AU - Iino, Keiko

AU - Uchitomi, Yosuke

AU - Ogawa, Setsuro

AU - Kita, Midori

AU - Kimijima, Izo

AU - Kondo, Hitoshi

AU - Shino, Michihiro

AU - Takumi, Yoko

AU - Tsuneto, Akira

AU - Hamaguchi, Keiko

AU - Matsumoto, Maki

AU - Mukaiyama, Taketo

AU - Yamamuro, Makoto

AU - Watanabe, Akihiko

AU - Setoyama, Osamu

AU - Hiraga, Kazuaki

PY - 2005/5

Y1 - 2005/5

N2 - Background: The Japanese Society for Palliative Medicine (JSPM) set guidelines for cancer pain management in 1999. However, the clinical effectiveness of the guidelines has not yet been examined. Methods: Two groups of consecutive patients with cancer admitted to 37 national hospitals (collaborating hospitals for pain management research in Japan) were recruited, one from August to September 1999 (who received the standard treatment in use before the distribution of JSPM guidelines) and the other from July 2000 to May 2001 (who received treatment after the distribution of JSPM guidelines). Demographics, type of cancer and other baseline information were recorded for both groups. In addition, the intensity of pain (evaluated on a 4-level scale of none, mild, moderate, severe; and a visual analog scale of 0 to 100), its duration, source and location were recorded at base line, 1 week and 2 weeks after the start of pain management for two groups and compared by statistical methods. Results: A total of 314 cancer patients received the standard pre-guidelines treatment from August to September 1999 and 106 patients received the post-guidelines treatment from July 2000 to May 2001. No significant differences have been observed between the two groups in terms of baseline characteristics. There were more patients with lung cancer in the pre-guidelines treatment group and more with gastric cancer in the post-guidelines treatment group. More oral opioids (P=0.004) and more adjuvant drugs such as nonsteroidal anti-inflammatory drugs (P=0.001) and hydroxyzine (P=0.001) were used in the post-guidelines treatment group than in the pre-guidelines treatment group and the opposite was true for intravenous (P = 0.022) and suppository (P = 0.041) opioids. More patients in the post-guidelines treatment group became pain free after 2 weeks compared to those in the pre-guidelines treatment group (14.7% vs. 8.8%) (P = 0.036). Moreover, significantly fewer adverse reactions and more recovery from the adverse reactions which did occur were found in the post-guidelines treatment group than in the pre-guidelines treatment group. Conclusion: The implementation of JSPM pain management guidelines for cancer patients was effective in increasing the proportion of patients relieved of pain and in reducing adverse reactions to opioids.

AB - Background: The Japanese Society for Palliative Medicine (JSPM) set guidelines for cancer pain management in 1999. However, the clinical effectiveness of the guidelines has not yet been examined. Methods: Two groups of consecutive patients with cancer admitted to 37 national hospitals (collaborating hospitals for pain management research in Japan) were recruited, one from August to September 1999 (who received the standard treatment in use before the distribution of JSPM guidelines) and the other from July 2000 to May 2001 (who received treatment after the distribution of JSPM guidelines). Demographics, type of cancer and other baseline information were recorded for both groups. In addition, the intensity of pain (evaluated on a 4-level scale of none, mild, moderate, severe; and a visual analog scale of 0 to 100), its duration, source and location were recorded at base line, 1 week and 2 weeks after the start of pain management for two groups and compared by statistical methods. Results: A total of 314 cancer patients received the standard pre-guidelines treatment from August to September 1999 and 106 patients received the post-guidelines treatment from July 2000 to May 2001. No significant differences have been observed between the two groups in terms of baseline characteristics. There were more patients with lung cancer in the pre-guidelines treatment group and more with gastric cancer in the post-guidelines treatment group. More oral opioids (P=0.004) and more adjuvant drugs such as nonsteroidal anti-inflammatory drugs (P=0.001) and hydroxyzine (P=0.001) were used in the post-guidelines treatment group than in the pre-guidelines treatment group and the opposite was true for intravenous (P = 0.022) and suppository (P = 0.041) opioids. More patients in the post-guidelines treatment group became pain free after 2 weeks compared to those in the pre-guidelines treatment group (14.7% vs. 8.8%) (P = 0.036). Moreover, significantly fewer adverse reactions and more recovery from the adverse reactions which did occur were found in the post-guidelines treatment group than in the pre-guidelines treatment group. Conclusion: The implementation of JSPM pain management guidelines for cancer patients was effective in increasing the proportion of patients relieved of pain and in reducing adverse reactions to opioids.

KW - Cancer pain

KW - Clinical effectiveness

KW - Japanese Society for Palliative Medicine

KW - Opioids and non-opioid analgesics

KW - Pain management

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=22444439449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22444439449&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 216

EP - 223

JO - Asian Medical Journal

JF - Asian Medical Journal

SN - 1346-8650

IS - 5

ER -